Back to the main directory
EarningsReview / Equity
- Ncc (Buy, TP: SEK125.00) - Q3e EPS cut on profit warning by DnB Markets
- Arovella Therapeutics - Positive collaboration with ALA-101 by Edison Investment Research
- musicMagpie - Weak Technology outright sales by Edison Investment Research
- Portobello - Offering value in tough times by Edison Investment Research
- SIGA Technologies - Monkeypox concern drives international TPOXX win by Edison Investment Research
- A new sense of focus by BNP Paribas Exane
- Investment Daily 28/09/2022 by BNP Paribas Exane
- INVEST SECURITIES - ESI : L'accélération de la croissance attendra - VENTE vs NEUTRE, OC 58€ (vs 65€) by Invest Securities
- Tears for fears (and 15 Q''s for management) by BNP Paribas Exane
- Volvo Cars (Sell, TP: SEK48.00) - Destination guidance cut by DnB Markets
- Hexpol (Buy, TP: SEK120.00) - Benefiting from large US exposure by DnB Markets
- Avanza Bank (Hold, TP: SEK170.00) - The price for higher NII by DnB Markets
- 1Spatial - Making GIS data useable for a variety of verticals by Edison Investment Research
- Context Therapeutics - Cash runway extended to Q124 by Edison Investment Research
- New peaks in FY23 by BNP Paribas Exane
- Push the button on ESG by BNP Paribas Exane
- INVEST SECURITIES - GRIFOLS : Un refinancement urgent pour juguler la baisse - ACHAT, OC 18,5€ (vs 22€) by Invest Securities
- Key Takeaways from Management Meetings by BNP Paribas Exane
- China Film Industry by HSBC
- Working to reduce costs but a hit on FY21/22 results by BNP Paribas Exane
- Disappointing H1 22, but green shoots visible by BNP Paribas Exane
- 6 concerns that lead us to $2.55 in EPS power by BNP Paribas Exane
- Volvo (Hold, TP: SEK175.00) - Cheap, no inflection point in sight by DnB Markets
- Aker BP (Buy, TP: NOK460.00) - Opportunity at an unusual discount by DnB Markets
- Solid fundamentals despite uncertainty by DnB Markets
- Jm Ab (No_rec, TP: SEK) - Guidance cuts look likely by DnB Markets
- Cohort - Order book supports return to growth by Edison Investment Research
- OSE Immunotherapeutics - Tedopi remains focus in FY22 by Edison Investment Research
- Regional REIT - Continuing to deliver income-led returns by Edison Investment Research
- Steelmaking surprises positively and orders are strong by BNP Paribas Exane
- Heading towards a 2023 goldilocks scenario by BNP Paribas Exane
- INVEST SECURITIES - LVMH : Prédominance du risque taux dans l'évaluation ? - NEUTRE, OC 631€ vs 702€ by Invest Securities
- Q422 Postview (+15 questions for management) by BNP Paribas Exane
- Round trip by BNP Paribas Exane
- Sats (Hold, TP: NOK7.00) - New training programme needed by DnB Markets
- Nordnet (Buy, TP: SEK146.00) - There is no rose without a thorn by DnB Markets
- September web-activity insights by DnB Markets
- Ebiquity - Strong uplift in operating margin by Edison Investment Research
- Vietnam Enterprise Investments - Access to Vietnam’s dynamic growth, at a discount by Edison Investment Research
- Boxing clever by BNP Paribas Exane
- Investment Daily 29/09/2022 by BNP Paribas Exane
- INVEST SECURITIES - TOOSLA : Scenario LT confirmé après un S1 de « mise en route » - ACHAT, OC 5,24€ (vs 6,14€) by Invest Securities
- 中国电影行业 by HSBC
- Strong set of Q2 results by BNP Paribas Exane
- Only the start of the Fall by BNP Paribas Exane
- Truss in the Lord (and 15 Questions) by BNP Paribas Exane
- BioArctic (Buy, TP: SEK220.00) - Strong data from ClarityAD by DnB Markets
- Equinor (Buy, TP: NOK450.00) - Set for strongest quarter ever by DnB Markets
- Vår Energi (Buy, TP: NOK48.00) - Yield story intact by DnB Markets
- abrdn Asian Income Fund - A reappraisal of the opportunities for AAIF by Edison Investment Research